Đang chuẩn bị liên kết để tải về tài liệu:
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-IMETRY): Protocol for a multicentre UK single arm phase II trial

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Thyroid cancer is the most common endocrine malignancy. Some advanced disease is, or becomes, resistant to radioactive iodine therapy (refractory disease); this holds poor prognosis of 10% 10-year overall survival. Whilst Sorafenib and Lenvatinib are now licenced for the treatment of progressive iodine refractory thyroid cancer, these treatments require continuing treatment and can be associated with significant toxicity. | Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy SEL-IMETRY Protocol for a multicentre UK single arm phase II trial

TÀI LIỆU LIÊN QUAN

Lecture Criminal investigation - Chapter 5: Field notes and investigating reporting

A technique for investigating nonlinear vibrations

Method of transmission matrix for investigating planar relative motions

A new approach for investigating corrugated laminated composite plates of wave form

Investigating monetary policy dynamics in Nigeria: The role of private investment

Investigating green brand equity and its driving forces

Báo cáo khoa học: "Investigating Pitch Accent Recognition in Non-native Speech"

Báo cáo khoa học: "Investigating Cue Selection and Placement in Tutorial Discourse"

Báo cáo khoa học: "Investigating GIS and Smoothing for Maximum Entropy Taggers"

Báo cáo khoa học: "Investigating a Generic Paraphrase-based Approach for Relation Extraction"
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.